- Home
- ABVC vs ONVO Comparison
ABVC vs ONVO Comparison
Compare ABVC & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ONVO
- Stock Information
- Founded
- ABVC 2015
- ONVO 2007
- Country
- ABVC United States
- ONVO United States
- Employees
- ABVC N/A
- ONVO N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABVC Health Care
- ONVO Health Care
- Exchange
- ABVC Nasdaq
- ONVO Nasdaq
- Market Cap
- ABVC 6.5M
- ONVO 6.7M
- IPO Year
- ABVC N/A
- ONVO N/A
- Fundamental
- Price
- ABVC $0.50
- ONVO $0.36
- Analyst Decision
- ABVC
- ONVO
- Analyst Count
- ABVC 0
- ONVO 0
- Target Price
- ABVC N/A
- ONVO N/A
- AVG Volume (30 Days)
- ABVC 361.4K
- ONVO 274.7K
- Earning Date
- ABVC 11-14-2024
- ONVO 02-06-2025
- Dividend Yield
- ABVC N/A
- ONVO N/A
- EPS Growth
- ABVC N/A
- ONVO N/A
- EPS
- ABVC N/A
- ONVO N/A
- Revenue
- ABVC $509,788.00
- ONVO $103,000.00
- Revenue This Year
- ABVC N/A
- ONVO $59.08
- Revenue Next Year
- ABVC N/A
- ONVO $18.24
- P/E Ratio
- ABVC N/A
- ONVO N/A
- Revenue Growth
- ABVC N/A
- ONVO N/A
- 52 Week Low
- ABVC $0.41
- ONVO $0.32
- 52 Week High
- ABVC $2.45
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- ABVC 36.66
- ONVO 39.56
- Support Level
- ABVC $0.47
- ONVO $0.34
- Resistance Level
- ABVC $0.52
- ONVO $0.43
- Average True Range (ATR)
- ABVC 0.04
- ONVO 0.05
- MACD
- ABVC -0.00
- ONVO -0.01
- Stochastic Oscillator
- ABVC 25.56
- ONVO 18.67
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.